| Bioactivity | Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties[1][2]. | ||||||||||||
| Invitro | Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair[1]. | ||||||||||||
| In Vivo | Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU)[1]. Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively[1]. Animal Model: | ||||||||||||
| Name | Troxipide | ||||||||||||
| CAS | 30751-05-4 | ||||||||||||
| Formula | C15H22N2O4 | ||||||||||||
| Molar Mass | 294.35 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Hongbin Guo, et al. Metabolites profiling and pharmacokinetics of troxipide and its pharmacodynamics in rats with gastric ulcer. Sci Rep. 2020 Aug 12;10(1):13619. [2]. K Kusugami, et al. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants. Dig Liver Dis. 2000 May;32(4):305-11. |